Jin Yichen, Qin Qianqian, Li Chao, Tang Houlin, Zhang Dapeng, Bai Wenqing, Chen Fangfang, Li Peilong, Duolaitiniyazi Pairidai, Ren Ruiqi, Li Dan, Xiang Nijuan, Shi Guoqing, Lyu Fan, Li Qun
National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
China CDC Wkly. 2025 Feb 14;7(7):233-238. doi: 10.46234/ccdcw2025.037.
This study aimed to analyze the epidemiological characteristics and clinical symptoms of mpox cases with and without human immunodeficiency virus (HIV) reported in China in 2023, providing evidence for coordinated prevention and control strategies for both infections.
All confirmed mpox cases reported in 2023 were extracted from China's Information System for Disease Control and Prevention. Data were collected from the surveillance system and epidemiological investigations. Statistical analyses were performed using SPSS 24.0, with group comparisons conducted using tests and chi-square tests.
Among 1,712 confirmed mpox cases in China during 2023, 802 (46.8%) were people with human immunodeficiency virus (PWH). Of the 1,702 male cases, 97.3% of PWH and 91.1% of those without HIV self-identified as men who have sex with men (MSM). Age distribution showed 79.4% of PWH and 87.6% of those without HIV were under 40 years old, while 64.2% of PWH and 71.3% of those without HIV were reported from eastern regions. Cardinal symptoms at diagnosis occurred at similar rates between those with and without HIV, including rash (90.9% . 93.4%), fever (52.5% 53.8%), and lymphadenopathy (23.8% 25.4%). Among coinfected cases, individuals diagnosed with HIV after mpox or within one year before mpox demonstrated higher rates of immunodeficiency and lower rates of HIV viral suppression.
Male mpox cases with HIV was more likely to be MSM, older, and reported from central and western regions compared to those without HIV. No significant differences were observed in cardinal symptom occurrence between groups. These findings emphasize the importance of implementing integrated prevention strategies targeting both HIV and mpox, particularly among key populations.
本研究旨在分析2023年中国报告的合并或未合并人类免疫缺陷病毒（HIV）的猴痘病例的流行病学特征和临床症状，为这两种感染的联合防控策略提供依据。
从中国疾病预防控制信息系统中提取2023年报告的所有确诊猴痘病例。数据从监测系统和流行病学调查中收集。使用SPSS 24.0进行统计分析，组间比较采用检验和卡方检验。
2023年中国1712例确诊猴痘病例中，802例（46.8%）为人类免疫缺陷病毒感染者（PWH）。在1702例男性病例中，97.3%的PWH和91.1%未感染HIV者自我认定为男男性行为者（MSM）。年龄分布显示，79.4%的PWH和87.6%未感染HIV者年龄在40岁以下，而64.2%的PWH和71.3%未感染HIV者来自东部地区。确诊时的主要症状在合并和未合并HIV者中发生率相似，包括皮疹（90.9% 对93.4%）、发热（52.5% 对53.8%）和淋巴结病（23.8% 对25.4%）。在合并感染病例中，猴痘后或猴痘前一年内确诊HIV的个体免疫缺陷发生率较高，HIV病毒抑制率较低。
与未感染HIV的男性猴痘病例相比，感染HIV的男性猴痘病例更可能是MSM，年龄较大，且来自中西部地区。两组间主要症状发生率未观察到显著差异。这些发现强调了实施针对HIV和猴痘的综合预防策略的重要性，特别是在重点人群中。
